GPBAR1 and metabolic dysfunction-associated steatotic liver disease: Previous studies have suggested that bile acid is associated with the occurrence and development of NAFLD and is a potential therapeutic target for NAFLD, especially in the pathways of farnesoid X receptor (FXR) and G protein‐coupled receptor superfamily (TGR5).